Elevation Oncology appoints Joseph Ferra as permanent CEO and Tammy Furlong as CFO

Elevation Oncology, Inc.

Joseph J. Ferra Jr. appointed President & CEO effective July 12, 2023; he steps down as CFO.
Tammy Furlong, previously VP of Finance, appointed CFO effective July 12, 2023.
Ferra's base salary increased to $600,000, target bonus 50%, and options for 35,000 shares.
Furlong's base salary increased to $430,000, target bonus 40%, and options for 53,433 shares.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Joseph J. Ferra, Jr.

President and Chief Executive Officer

Elevation Oncology, Inc.

Effective: 2023-07-12
Filed: July 13, 2023, 7:59 PM ET

appointed Joseph J. Ferra, Jr. as (i) President and Chief Executive Officer of the Company and (ii) a member of the Board, to serve as a Class I director with an initial term expiring at the Company’s 2025 Annual Meeting of Stockholders, in each case, effective as of July 12, 2023

Appointed

Joseph J. Ferra, Jr.

member of the Board

Elevation Oncology, Inc.

Effective: 2023-07-12
Filed: July 13, 2023, 7:59 PM ET

appointed Joseph J. Ferra, Jr. as (i) President and Chief Executive Officer of the Company and (ii) a member of the Board, to serve as a Class I director with an initial term expiring at the Company’s 2025 Annual Meeting of Stockholders, in each case, effective as of July 12, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph J. Ferra, Jr. was appointed as President and Chief Executive Officer at Elevation Oncology, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

appointed Joseph J. Ferra, Jr. as (i) President and Chief Executive Officer of the Company and (ii) a member of the Board, to serve as a Class I director with an initial term expiring at the Company’s 2025 Annual Meeting of Stockholders, in each case, effective as of July 12, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph J. Ferra, Jr. was appointed as member of the Board at Elevation Oncology, Inc..

Action: appointed
Role: member of the Board

Exact text from the filing

appointed Joseph J. Ferra, Jr. as (i) President and Chief Executive Officer of the Company and (ii) a member of the Board, to serve as a Class I director with an initial term expiring at the Company’s 2025 Annual Meeting of Stockholders, in each case, effective as of July 12, 2023

View on SEC.gov

Source: SEC EDGAR

accession 0001558370-23-011852

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.